Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Merz Therapeutics GmbH

Contact Research Centre

Migraine

Not recruiting

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Merz Therapeutics GmbH

Contact Research Centre

Migraine

Not recruiting

Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

Investigational

Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

Investigational

Denmark

Participants:18–64 years
Substances:Lu Ag09222
Sponsor:H. Lundbeck A/S

Contact Research Centre

Migraine

Not recruiting

Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

Investigational

Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:MEDI0618
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Multiple sclerosis+1

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo

Study on the Effectiveness and Safety of Ocrelizumab for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Methylprednisolone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Schizophrenia

Not recruiting

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo

Denmark

Participants:18–64 years
Substances:Iclepertin
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:Asundexian
Sponsor:Bayer AG

Contact Research Centre

Other cities in Denmark

The busiest research cities in the country

All 48 cities in Denmark

Clinical research in Glostrup

What the registry says about research in the country

01 Neurological Disorders

Extensive research focusing on multiple sclerosis treatments, including trials evaluating new therapeutic approaches and comparing different drug efficacies. Studies range from testing novel compounds to assessing higher doses of established treatments.

Multiple Sclerosis Variants
Relapsing-Remitting MS
Progressive MS

Additional investigations include treatments for migraine and nerve pain conditions.

02 Psychiatric Conditions

Innovative trials exploring treatments for schizophrenia and related psychotic disorders, with a focus on cognitive improvement and symptom management. Research includes GABA receptor modulation and novel therapeutic approaches.

First Episode Psychosis
Cognitive Impairment
Negative Symptoms

Studies emphasize both early intervention and long-term treatment outcomes.

03 Ophthalmology

Comprehensive research in eye disorders, including glaucoma treatments, retinal conditions, and corneal diseases. Studies evaluate both medical and surgical interventions for various ocular conditions.

Ocular Hypertension
Retinitis Pigmentosa
Corneal Dystrophy

Trials include novel drug delivery systems and gene therapy approaches.

Back to Denmark All countries